Cargando…
Dual Antiplatelet Therapy in Coronary Artery Disease
Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The newer antiplatelets ticagrelor and prasugrel have demonstrated superiority over clopidogrel. While prasugrel demonstrated benef...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584687/ https://www.ncbi.nlm.nih.gov/pubmed/32804330 http://dx.doi.org/10.1007/s40119-020-00197-0 |
_version_ | 1783599647744327680 |
---|---|
author | Sharma, Raghav Kumar, Prathap Prashanth, S. P. Belagali, Yogesh |
author_facet | Sharma, Raghav Kumar, Prathap Prashanth, S. P. Belagali, Yogesh |
author_sort | Sharma, Raghav |
collection | PubMed |
description | Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The newer antiplatelets ticagrelor and prasugrel have demonstrated superiority over clopidogrel. While prasugrel demonstrated benefit in patients scheduled for percutaneous intervention (PCI), benefits of ticagrelor were seen irrespective of the treatment strategy. Current guidelines recommend the use of DAPT for 1 year in all patients with ACS. Ticagrelor 60 mg is recommended for up to 3 years in high-risk patients. DAPT and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE DAPT) scores are tools to support decision-making in deciding duration of dual antiplatelet therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40119-020-00197-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7584687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-75846872020-10-29 Dual Antiplatelet Therapy in Coronary Artery Disease Sharma, Raghav Kumar, Prathap Prashanth, S. P. Belagali, Yogesh Cardiol Ther Review Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The newer antiplatelets ticagrelor and prasugrel have demonstrated superiority over clopidogrel. While prasugrel demonstrated benefit in patients scheduled for percutaneous intervention (PCI), benefits of ticagrelor were seen irrespective of the treatment strategy. Current guidelines recommend the use of DAPT for 1 year in all patients with ACS. Ticagrelor 60 mg is recommended for up to 3 years in high-risk patients. DAPT and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE DAPT) scores are tools to support decision-making in deciding duration of dual antiplatelet therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40119-020-00197-0) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-08-17 2020-12 /pmc/articles/PMC7584687/ /pubmed/32804330 http://dx.doi.org/10.1007/s40119-020-00197-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Sharma, Raghav Kumar, Prathap Prashanth, S. P. Belagali, Yogesh Dual Antiplatelet Therapy in Coronary Artery Disease |
title | Dual Antiplatelet Therapy in Coronary Artery Disease |
title_full | Dual Antiplatelet Therapy in Coronary Artery Disease |
title_fullStr | Dual Antiplatelet Therapy in Coronary Artery Disease |
title_full_unstemmed | Dual Antiplatelet Therapy in Coronary Artery Disease |
title_short | Dual Antiplatelet Therapy in Coronary Artery Disease |
title_sort | dual antiplatelet therapy in coronary artery disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584687/ https://www.ncbi.nlm.nih.gov/pubmed/32804330 http://dx.doi.org/10.1007/s40119-020-00197-0 |
work_keys_str_mv | AT sharmaraghav dualantiplatelettherapyincoronaryarterydisease AT kumarprathap dualantiplatelettherapyincoronaryarterydisease AT prashanthsp dualantiplatelettherapyincoronaryarterydisease AT belagaliyogesh dualantiplatelettherapyincoronaryarterydisease |